Baseline Clinical and Neuropsychological Characteristics of Amyloid PET-Confirmed Alzheimer’s Disease Treated With Lecanemab: Early Experience at a Tertiary Hospital in Korea
Dementia and Neurocognitive Disorders · 2026 · 25 (2) · 137
DOI: 10.12779/dnd.2026.25.2.137 ↗Kurz gefasst
Fallbericht in der Zeitschrift Dementia and Neurocognitive Disorders, 2026. Verfasst von Hyeongjin Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Alzheimer's Disease Convergence Research Center, Samsung Medical Center, Seoul, Korea. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Demenz
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Alzheimer's Disease Convergence Research Center, Samsung Medical Center, Seoul, Korea.
- Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Korea.
ORCID-Profile: Hyeongjin Kim, Jeongha Lee, Hee Kyung Park, Kyung Bok Lee, Jun Pyo Kim, Byung Hwa Lee
Zitieren
APA
Kim, H., Lee, J., Park, H. K., Lee, K. B., Kim, J. P., & Lee, B. H. (2026). Baseline Clinical and Neuropsychological Characteristics of Amyloid PET-Confirmed Alzheimer’s Disease Treated With Lecanemab: Early Experience at a Tertiary Hospital in Korea. Dementia and Neurocognitive Disorders, 25(2), 137. https://doi.org/10.12779/dnd.2026.25.2.137
Vancouver
Kim H, Lee J, Park HK, Lee KB, Kim JP, Lee BH. Baseline Clinical and Neuropsychological Characteristics of Amyloid PET-Confirmed Alzheimer’s Disease Treated With Lecanemab: Early Experience at a Tertiary Hospital in Korea. Dementia and Neurocognitive Disorders. 2026;25(2):137. doi:10.12779/dnd.2026.25.2.137
BibTeX
@article{Kim2026,
author = {Kim, Hyeongjin and Lee, Jeongha and Park, Hee Kyung and Lee, Kyung Bok and Kim, Jun Pyo and Lee, Byung Hwa},
title = {Baseline Clinical and Neuropsychological Characteristics of Amyloid PET-Confirmed Alzheimer’s Disease Treated With Lecanemab: Early Experience at a Tertiary Hospital in Korea},
journal = {Dementia and Neurocognitive Disorders},
year = {2026},
volume = {25},
number = {2},
pages = {137},
doi = {10.12779/dnd.2026.25.2.137}
}
EUVIMED